Payment overview · 2025
General Payments
$1,769.80
77 reported records · 10 companies
Healthcare provider profile · identity verified
Ronald Ray Alligood, ACNP, PHD
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Acute Care · CHAPEL HILL, NC · NPI 1407936800
Verified facts
What the public records show
CMS Open Payments records show Ronald Ray Alligood, ACNP, PHD received $1,769.80 in general payments during 2025 across 77 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 21.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $386.09 | 21.8% | 14 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $385.24 | 21.8% | 20 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $367.44 | 20.8% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $244.21 | 13.8% | 15 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $151.42 | 8.6% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $57.46 | 3.2% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $57.03 | 3.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.55 | 2.5% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $42.55 | 2.4% | 1 | 2025 |
| Luye Pharma (USA) Ltd. | Unresolved — no canonical attribution shown | $33.81 | 1.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,660.31 | 76 |
| Education | $109.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $385.24 | 20 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $263.22 | 19 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $244.21 | 15 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $218.78 | 9 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $211.07 | 11 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $200.68 | 4 | 2025 |
Source payment records
|
|||||
| ABILIFY MAINTENA Normalized: abilify maintena |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $153.64 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $151.42 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $57.03 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $44.55 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $42.55 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $39.17 | 3 | 2025 |
Source payment records
|
|||||
| ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release |
Drug | Luye Pharma (USA) Ltd. | $33.81 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $29.55 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 118 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 109 | 33 |
| Atorvastatin Calcium | Atorvastatin Calcium | 105 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 28 |
| Omeprazole | Omeprazole | 83 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 81 | 24 |
| Trazodone Hcl | Trazodone Hcl | 80 | 30 |
| Metformin Hcl Er | Metformin Hcl | 63 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 61 | 20 |
| Farxiga | Dapagliflozin Propanediol | 55 | 18 |
| Losartan Potassium | Losartan Potassium | 51 | 17 |
| Sertraline Hcl | Sertraline Hcl | 51 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 21 |
| Glipizide Er | Glipizide | 47 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 47 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 18 |
| Furosemide | Furosemide | 43 | 15 |
| Alprazolam | Alprazolam | 42 | 15 |
| Lisinopril | Lisinopril | 42 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 17 |
| Buspirone Hcl | Buspirone Hcl | 40 | 17 |
| Clonazepam | Clonazepam | 40 | 16 |
| Jardiance | Empagliflozin | 37 | suppressed |
| Olanzapine | Olanzapine | 37 | 15 |
| Mirtazapine | Mirtazapine | 36 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 17 |
| Eliquis | Apixaban | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 13 |
| Aripiprazole | Aripiprazole | 32 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 14 |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 28 | 12 |
| Ozempic | Semaglutide | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 25 | suppressed |
| Metformin Hcl | Metformin Hcl | 25 | 12 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Risperidone | Risperidone | 18 | 12 |
| Clotrimazole | Clotrimazole | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,769.80 · 77 records | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, AUSTEDO XR, ERZOFRI EXTENDED-RELEASE, FANAPT, HETLIOZ, INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, LYBALVI, REXULTI, SUBLOCADE, UZEDY, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error